Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-Trastuzumab PET Imaging in HER2+ Breast Cancer
NCT03321045Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2017
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 89Zr-trastuzumab in breast cancer, sponsored by University of Alabama at Birmingham. Primary endpoint: Investigate the use of [89Zr]-Df-Trastuzumab as a HER2 imaging agent at 24 months. Started Nov 2017; status: recruiting.
02
Drugs
89Zr-trastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03321045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03321045.